Presently, breast cancer (BC) is one of the most common malignancies diagnosed and the
leading cause of tumor-related deaths among women worldwide. Cell cycle dysregulation is …

TGFβ signaling and the DNA damage response (DDR) are two cellular toolboxes with a
strong impact on cancer biology. While TGFβ as a pleiotropic cytokine affects essentially all …

Non–small cell lung cancers that harbor concurrent KRAS and TP53 (KP) mutations are
immunologically warm tumors with partial responsiveness to anti–PD-(L) 1 blockade; …

The use of cell cycle inhibitors has necessitated a better understanding of the cell cycle in
tumor biology to optimize the therapeutic approach. Cell cycle aberrations are common in …

Adaptions to therapeutic pressures exerted on cancer cells enable malignant progression of
the tumor, culminating in escape from programmed cell death and development of resistant …

Simple Summary KRAS is the most common oncogene in human cancers and has long
been considered ''undruggable''—that is, until recently, when covalent inhibitors that …

Lung cancer is a highly aggressive and metastatic disease responsible for approximately
25% of all cancer-related deaths in the United States. Using high-throughput in vitro and in …

Keratin 8 (KRT8) is the major component of the intermediate filament cytoskeleton and
aberrant expression in multiple tumors. However, the role of KRT8 in lung adenocarcinoma …

Non-coding RNAs have shown key roles in cancer and among them, short RNA molecules
are known as microRNAs (miRNAs). These molecules have length less than 25 nucleotides …

Adagrasib is a recently US FDA-approved novel KRASG12C targeted therapy with clinical
efficacy in patients with advanced, pretreated KRASG12C-mutated non-small-cell lung …